Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

NCT01725100 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01725100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01725100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
February 5, 2013
Completion date
January 30, 2015
Enrollment
80 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer